Rituximab

Rituximab maintenance following induction immunochemotherapy conferred durable PFS compared with observation among patients with follicular lymphoma, according to long-term results of the randomized phase 3 PRIMA study published in Journal of Clinical Oncology.

A 77-year-old white woman presented to the emergency department with worsening floaters and decreased vision in the left eye. She reported that she initially noticed floaters in the left eye 6 months ago, but over the past few months, the floaters had turned brown and coalesced to form a dark cloud. Her husband also noticed new right-hand clumsiness and word-finding difficulties for the past 3 days. She denied fevers, chills, weight loss and shortness of breath.

A combination of ibrutinib and rituximab improved PFS and OS compared with standard chemoimmunotherapy among patients with previously untreated chronic lymphocytic leukemia, according to results of a randomized, phase 3 trial published in The New England Journal of Medicine.

In this video, Noah Merin, MD, PhD, from the Blood and Marrow Transplantation Program and assistant professor of medicine at Cedars-Sinai Medical Center, discussed bispecific antibodies, their toxicities and their potential in follicular lymphoma.

In this video, Noah Merin, MD, PhD, from the Blood and Marrow Transplantation Program and assistant professor of medicine at Cedars-Sinai Medical Center, discussed first-line treatments and options for relapsed or refractory follicular lymphoma.

In this video, Bijal Shah, MD, MS, an associate professor in the malignant hematology department at Moffitt Cancer Center, discussed updates to the SHINE trial, and its role in the treatment of mantle cell lymphoma, as well as findings of ZUMA-2 and how it impacts clinical practice.